Perfect Medical Health Management Limited (1830) AI Stock Analysis

• Market Cap: HK$1.57B
• Dividend Yield: 9.92%
• Average Volume (3M): 414.58K
• Price to Earnings (P/E): 9.8
• Beta (1Y): 0.73
• Revenue Growth: -23.31%
• EPS Growth: -44.61%
• Country: HK
• Employees: 1,161
• Sector: Healthcare
• Sector Strength: 45
• Industry: Personal Products & Services
• EPS (TTM): 0.07
• Shares Outstanding: 1,256,197,800
• 10 Day Avg. Volume: 497,109
• 30 Day Avg. Volume: 414,582
• PEG Ratio: -0.38
• Price to Book (P/B): 7.51
• Price to Sales (P/S): 2.53
• P/FCF Ratio: 9.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: HK$1.50 ▲(20.00% Upside)

The stock's overall score is driven primarily by its strong valuation, offering a low P/E ratio and high dividend yield. However, the financial performance is hindered by declining revenue and cash flow growth, and technical indicators suggest a bearish trend. The absence of earnings call data and notable corporate events limits additional insights.

Positive Factors

Corporate Governance

Enhancing corporate governance with a diverse and independent committee structure strengthens the company's reputation and aligns with best practices, potentially improving investor confidence and market perception.

Profitability Margins

High profitability margins indicate efficient operations and pricing power, which can sustain the company's financial health and competitive positioning over the long term.

Dividend Policy

A consistent dividend policy reflects stable financial performance and a commitment to shareholder returns, enhancing investor trust and potentially attracting income-focused investors.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in market demand and competition, which could impact the company's ability to sustain growth and profitability in the medium term.

Profit Decline

A sharp decline in profit reflects potential operational inefficiencies or market pressures, which could strain financial resources and affect long-term strategic initiatives.

Cash Flow Challenges

Decreasing free cash flow growth may limit the company's ability to invest in new opportunities and manage financial obligations, potentially impacting future expansion and stability.

Perfect Medical Health Management Limited Business Overview & Revenue Model

Company Description

Perfect Medical Health Management Limited, an investment holding company, provides medical and aesthetic medical services in Hong Kong, China, Macau, Singapore, and Australia. It offers medical beauty, hair growth, pain management, preventive care, and fertility care services. The company also provides advertising, charitable, and management services; holds trademarks; and rents equipment. In addition, it operates service centers. The company was formerly known as Perfect Shape Medical Limited and changed its name to Perfect Medical Health Management Limited in June 2021. Perfect Medical Health Management Limited was founded in 2003 and is headquartered in Mong Kok, Hong Kong.

How the Company Makes Money

The company generates revenue primarily through subscription-based services for its health management platforms, which provide healthcare providers with access to telemedicine tools, patient management systems, and clinical data analytics. Additional revenue streams include consulting services for healthcare organizations looking to implement technology-driven solutions, as well as partnerships with pharmaceutical companies for data analytics and patient engagement initiatives. Significant collaborations with hospitals and clinics also contribute to its earnings by expanding its service offerings and user base.

Perfect Medical Health Management Limited Financial Statement Overview

Summary

The company shows strong profitability with healthy margins and a stable balance sheet. However, it faces challenges with declining revenue and free cash flow growth, indicating potential areas for improvement in sustaining growth momentum.

Income Statement

The company has experienced a decline in revenue growth, with a notable decrease of 12.94% in the latest year. However, it maintains healthy profitability margins, with a gross profit margin of 63.77% and a net profit margin of 18.34%. The EBIT and EBITDA margins are also strong at 23.37% and 39.19%, respectively. Despite the revenue decline, the company demonstrates solid profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.57, indicating a balanced leverage position. The return on equity is robust at 54.45%, reflecting efficient use of equity to generate profits. The equity ratio stands at 40.59%, suggesting a stable financial structure with adequate equity backing.

Cash Flow

The company has faced a decline in free cash flow growth, down by 16.77% in the latest year. However, the operating cash flow to net income ratio is strong at 0.83, and the free cash flow to net income ratio is 0.90, indicating effective cash generation relative to net income. Despite the decline in free cash flow growth, the company maintains a solid cash flow position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.13B	1.13B	1.39B	1.39B	1.35B	1.09B
Gross Profit	614.35M	719.22M	911.37M	662.60M	689.93M	553.44M
EBITDA	376.81M	441.97M	596.91M	592.40M	602.84M	474.13M
Net Income	206.90M	206.90M	315.80M	315.64M	305.25M	284.63M
Balance Sheet
Total Assets	935.91M	935.91M	1.22B	1.30B	1.28B	1.48B
Cash, Cash Equivalents and Short-Term Investments	386.80M	386.80M	567.40M	656.85M	454.37M	532.89M
Total Debt	216.65M	216.65M	268.73M	240.35M	311.07M	261.60M
Total Liabilities	557.18M	557.18M	725.00M	684.02M	786.93M	795.52M
Stockholders Equity	379.95M	379.95M	497.51M	612.27M	494.27M	684.85M
Cash Flow
Free Cash Flow	298.23M	298.23M	445.50M	533.81M	372.16M	527.69M
Operating Cash Flow	332.88M	332.88M	497.12M	560.55M	516.71M	605.91M
Investing Cash Flow	-173.23M	-171.93M	162.56M	-222.51M	8.05M	-300.82M
Financing Cash Flow	-477.95M	-477.95M	-520.97M	-335.02M	-565.97M	-394.41M

Perfect Medical Health Management Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1830, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.31, and below the 200-day MA of 1.60, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.95 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1830.

Perfect Medical Health Management Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1161	73 Outperform	HK$639.72M	7.87	24.41%	5.98%	-0.19%	19.04%
1830	66 Neutral	HK$1.57B	9.77	36.52%	9.92%	-23.31%	-44.61%
8603	66 Neutral	HK$5.16B	101.44	49.25%	―	56.28%	-9.91%
1827	55 Neutral	HK$380.00M	34.93	7.67%	―	-20.59%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0919	46 Neutral	HK$69.65M	3.76	10.10%	―	-3.40%	515.63%

Perfect Medical Health Management Limited Corporate Events

Perfect Medical Clarifies No Performance Targets on Newly Granted Share Options

Perfect Medical Health Management Limited has issued a supplemental announcement clarifying that recently granted share options to grantees under its share option scheme will not carry specific performance targets. The board and remuneration committee argue that the scheme’s design—linking option value to the company’s share price and imposing a vesting period—already sufficiently aligns the interests of grantees with those of the company and its shareholders, incentivising long-term commitment and broad-based contribution to the Group’s overall performance and development.

The most recent analyst rating on (HK:1830) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Perfect Medical Health Management Limited stock, see the HK:1830 Stock Forecast page.

Perfect Medical Grants Share Options to Employees to Strengthen Long-Term Alignment

Perfect Medical Health Management Limited has granted 3,768,000 share options to eligible employees under its 2021 share option scheme, representing about 0.30% of its issued share capital as of 7 January 2026. The options, exercisable at HK$1.27 per share over a ten-year period and vesting in full on the first anniversary of the grant date after a 12‑month non-exercise period, carry no performance targets and are designed to recognize past contributions, incentivize staff retention, and align employees’ interests with those of the company and its shareholders, underscoring the group’s focus on long-term performance and employee engagement.

The most recent analyst rating on (HK:1830) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Perfect Medical Health Management Limited stock, see the HK:1830 Stock Forecast page.

Perfect Medical Health Management Limited Reports Revenue Decline and Profit Recovery

Perfect Medical Health Management Limited reported a 21.7% decrease in revenue to HK$485.9 million for the six months ended September 30, 2025. Despite a 32.7% decrease in profit attributable to equity holders, the company showed a strong recovery with a 43.4% increase compared to the previous six-month period, reaching HK$94.8 million. The company proposed an interim dividend of HK7.6 cents per share, maintaining a dividend payout ratio of 101.3%, consistent with its 11-year history of 100% or above payout ratios.

The most recent analyst rating on (HK:1830) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Perfect Medical Health Management Limited stock, see the HK:1830 Stock Forecast page.

Perfect Medical Announces Interim Dividend for 2025

Perfect Medical Health Management Limited has announced an interim cash dividend of HKD 0.076 per share for the six months ending September 30, 2025. The dividend will be paid on December 31, 2025, with the ex-dividend date set for December 12, 2025. This announcement reflects the company’s ongoing commitment to delivering value to its shareholders and may positively influence its market positioning by showcasing financial stability and shareholder confidence.

The most recent analyst rating on (HK:1830) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Perfect Medical Health Management Limited stock, see the HK:1830 Stock Forecast page.

Perfect Medical Health Issues Profit Warning Amidst Declining Consumer Spending

Perfect Medical Health Management Limited has issued a profit warning, indicating a significant decline in profits for the six months ending September 2025, compared to the same period in 2024. The decrease in profit, expected to be between HK$93 million and HK$98 million, is attributed to reduced consumer spending due to increased outbound travel by Hong Kong residents and a cautious consumption sentiment in the company’s operating regions. The company advises caution to shareholders and investors as the interim results are yet to be finalized.

The most recent analyst rating on (HK:1830) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Perfect Medical Health Management Limited stock, see the HK:1830 Stock Forecast page.

Perfect Medical Health Management Limited Issues Profit Warning for 2025

Perfect Medical Health Management Limited has issued a profit warning, indicating that its profit attributable to shareholders for the six months ending September 30, 2025, is expected to be between HK$93 million and HK$98 million, down from HK$141 million in the same period in 2024. However, this represents a significant increase of at least 40% compared to the second half of the financial year 2025. The company is still finalizing its interim results, and stakeholders are advised to exercise caution due to the preliminary nature of the data.

The most recent analyst rating on (HK:1830) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Perfect Medical Health Management Limited stock, see the HK:1830 Stock Forecast page.

Perfect Medical Health Management to Review Interim Results and Dividend

Perfect Medical Health Management Limited has announced a board meeting scheduled for November 28, 2025, to approve and publish the interim results for the six months ending September 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

The most recent analyst rating on (HK:1830) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Perfect Medical Health Management Limited stock, see the HK:1830 Stock Forecast page.